Search

Displaying results 5701 - 5710 of 6198 in total
  1. Drug

    Thyrotropin alfa

    go.drugbank.com/drugs/DB00024
    ApprovedInvestigationalVet approved

    It is a heterodimeric glycoprotein comprised of two non-covalently linked subunits, an alpha subunit of 92 amino acid residues containing two N-linked glycosylation sites and a beta subunit of 112 residues

  2. Drug

    RGN6024

    go.drugbank.com/drugs/DB33059
    Experimental

    RGN6024 remains investigational and is not an approved drug. … It is designed as an orally administered, blood-brain barrier penetrant therapy for brain cancers, especially glioblastoma.

  3. Drug

    IDD-3

    go.drugbank.com/drugs/DB05427
    Experimental

    IDD-3 is a therapeutic specific immunostimulant developed by IDM Pharma in partnership with sanofi-aventis. It consists of mature dendritic cells loaded with lysates from melanoma tumor cell lines.

  4. Drug

    Putrescine

    go.drugbank.com/drugs/DB01917
    Investigational

    Putrescine is a toxic diamine formed by putrefaction from the decarboxylation of arginine and ornithine. Putrescine is a solid. This compound belongs to the polyamines.

  5. Drug

    Neramexane

    go.drugbank.com/drugs/DB04926
    Investigational

    Neramexane is a low-to-moderate affinity uncompetitive NMDA receptor antagonist.

  6. Drug

    GI-101

    go.drugbank.com/drugs/DB17243
    Investigational

    GI-101 is a bi-specific fragment crystallizable region (Fc) fusion protein containing a cluster of differentiation 80 ectodomain as an N-terminal moiety and interleukin-2 variant as a C-terminal moiety

  7. Drug

    Ty800

    go.drugbank.com/drugs/DB04989
    Investigational

    It is being developed by AVANT Immunotherapeutics, Inc.

  8. Drug

    AC-003

    go.drugbank.com/drugs/DB22691
    Investigational

    [L53458,L53463] By inhibiting RIPK1 kinase activity, AC-003 thereby inhibits RIPK1-mediated cell death and inflammation.

  9. Drug

    AGS-16C3F

    go.drugbank.com/drugs/DB17551
    Investigational

    AGS 16C3F is an intravenously administered, anti-ectonucleotide pyrophosphatase/phosphodiesterase 3 (ENPP3) antibody-drug conjugate.

  10. Drug

    Lemzoparlimab

    go.drugbank.com/drugs/DB17572
    Investigational

    Lemzoparlimab is under investigation in clinical trial NCT04912063 (Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Partic...